Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA504861
Max Phase: Preclinical
Molecular Formula: C34H31FN4O4
Molecular Weight: 578.64
Molecule Type: Small molecule
Associated Items:
ID: ALA504861
Max Phase: Preclinical
Molecular Formula: C34H31FN4O4
Molecular Weight: 578.64
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCOc1cccc(-n2cc(C(=O)N3CCN(c4cc(C(=O)O)c5ccccc5c4)CC3)nc2-c2ccc(C)cc2F)c1
Standard InChI: InChI=1S/C34H31FN4O4/c1-3-43-26-9-6-8-24(19-26)39-21-31(36-32(39)28-12-11-22(2)17-30(28)35)33(40)38-15-13-37(14-16-38)25-18-23-7-4-5-10-27(23)29(20-25)34(41)42/h4-12,17-21H,3,13-16H2,1-2H3,(H,41,42)
Standard InChI Key: AACZCKZTUMTPKO-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 578.64 | Molecular Weight (Monoisotopic): 578.2329 | AlogP: 6.20 | #Rotatable Bonds: 7 |
Polar Surface Area: 87.90 | Molecular Species: ACID | HBA: 6 | HBD: 1 |
#RO5 Violations: 2 | HBA (Lipinski): 8 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 4.34 | CX Basic pKa: 2.68 | CX LogP: 6.48 | CX LogD: 3.73 |
Aromatic Rings: 5 | Heavy Atoms: 43 | QED Weighted: 0.25 | Np Likeness Score: -1.41 |
1. Berger R, Zhu C, Hansen AR, Harper B, Chen Z, Holt TG, Hubert J, Lee SJ, Pan J, Qian S, Reitman ML, Strack AM, Weingarth DT, Wolff M, Macneil DJ, Weber AE, Edmondson SD.. (2008) 2-Substituted piperazine-derived imidazole carboxamides as potent and selective CCK1R agonists for the treatment of obesity., 18 (17): [PMID:18684621] [10.1016/j.bmcl.2008.07.083] |
2. Zhu C, Hansen AR, Bateman T, Chen Z, Holt TG, Hubert JA, Karanam BV, Lee SJ, Pan J, Qian S, Reddy VB, Reitman ML, Strack AM, Tong V, Weingarth DT, Wolff MS, MacNeil DJ, Weber AE, Duffy JL, Edmondson SD.. (2008) Discovery of imidazole carboxamides as potent and selective CCK1R agonists., 18 (15): [PMID:18614364] [10.1016/j.bmcl.2008.06.057] |
Source(1):